Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Georgia
Clinical trial register · United States · industry-sponsored

Clinical Trials in Georgia, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Nov 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4975
Recruiting now
open to new participants
2181
Lead sponsors
across recruiting studies
Top states
California 5328 Florida 4488 Illinois 2493 Georgia 2364 Arizona 2269
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca104 Eli Lilly and Company92 Merck Sharp & Dohme LLC72 AbbVie69 Janssen Research & Development, LLC66 Novartis Pharmaceuticals65 Pfizer51 Sanofi50 Bristol-Myers Squibb48 Hoffmann-La Roche47 Novo Nordisk A/S34 Gilead Sciences32 GlaxoSmithKline29 Boehringer Ingelheim27 Amgen27 Takeda25 Incyte Corporation23 Regeneron Pharmaceuticals22 Edwards Lifesciences20 Abbott Medical Devices20 Boston Scientific Corporation17 Genmab14 Daiichi Sankyo13 W.L.Gore & Associates13 Vertex Pharmaceuticals Incorporated12 Alexion Pharmaceuticals, Inc.11 Neurocrine Biosciences11 Celgene11 Axsome Therapeutics, Inc.10 Medtronic Cardiovascular9 ViiV Healthcare9 Astellas Pharma Global Development, Inc.9 Exelixis9 Jazz Pharmaceuticals8 Intra-Cellular Therapies, Inc.8 Bayer8 Genentech, Inc.8 Alkermes, Inc.8 BioMarin Pharmaceutical7 Ipsen7 Biogen7 Biohaven Therapeutics Ltd.7 ModernaTX, Inc.7 Ionis Pharmaceuticals, Inc.7 BioNTech SE7 Seagen, a wholly owned subsidiary of Pfizer7 Immunovant Sciences GmbH6 Agios Pharmaceuticals, Inc.6 Xenon Pharmaceuticals Inc.6 United Therapeutics6 Alnylam Pharmaceuticals6 Eisai Inc.6 Vanda Pharmaceuticals6 Amicus Therapeutics6 BeOne Medicines6 Karuna Therapeutics, Inc., a Bristol Myers Squibb company6 TransMedics6 DualityBio Inc.5 CSL Behring5 Otsuka Pharmaceutical Development & Commercialization, Inc.5 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company5 Kailera5 Celldex Therapeutics5 Kite, A Gilead Company5 Medtronic5 Bolton Medical5 ReCor Medical, Inc.4 Medtronic Cardiac Ablation Solutions4 argenx4 Philogen S.p.A.4 M.A. Med Alliance S.A.4 Mirati Therapeutics Inc.4 Revolution Medicines, Inc.4 ImmunityBio, Inc.4 Medtronic Cardiac Surgery4 Apellis Pharmaceuticals, Inc.4 Johnson & Johnson Enterprise Innovation Inc.4 Ono Pharmaceutical Co., Ltd.4 UCB Biopharma SRL4 Alto Neuroscience4 Mirum Pharmaceuticals, Inc.4 Tesaro, Inc.4 Viking Therapeutics, Inc.4 JenaValve Technology, Inc.4 GT Medical Technologies, Inc.4 Coherus Oncology, Inc.4 Shockwave Medical, Inc.4 Smith & Nephew, Inc.4 Galderma R&D3 Loxo Oncology, Inc.3 Orca Biosystems, Inc.3 Guardant Health, Inc.3 IDEAYA Biosciences3 Edgewise Therapeutics, Inc.3 Zydus Therapeutics Inc.3 Abiomed Inc.3 Iantrek, Inc.3 Summit Therapeutics3 EMD Serono Research & Development Institute, Inc.3 AtriCure, Inc.3 Syndax Pharmaceuticals3 Xencor, Inc.3 TriGemX Bio, Inc.3 Ascentage Pharma Group Inc.3 Madrigal Pharmaceuticals, Inc.3 MapLight Therapeutics3 Replimune, Inc.3 Intuitive Surgical3 Acerta Pharma BV3 Blueprint Medicines Corporation3 LEO Pharma3 Chiesi Farmaceutici S.p.A.3 4D Molecular Therapeutics3 Corcept Therapeutics3 Definium Therapeutics US, Inc.3 Bausch Health Americas, Inc.3 Veradermics, Inc.3 Cytokinetics3 Sanofi Pasteur, a Sanofi Company3 SystImmune Inc.3 TG Therapeutics, Inc.3 Annovis Bio Inc.3 Ascendis Pharma Endocrinology Division A/S3 Harmony Biosciences Management, Inc.3 Dompé Farmaceutici S.p.A3 Taiho Oncology, Inc.3 Tempus AI3 Alpha Tau Medical LTD.3 Centessa Pharmaceuticals (UK) Limited3 Nektar Therapeutics3 LB Pharmaceuticals Inc.3 C4 Therapeutics, Inc.3 Arcus Biosciences, Inc.3 Vima Therapeutics3 Crinetics Pharmaceuticals Inc.3 Bellicum Pharmaceuticals3 Crystalys Therapeutics3 Travere Therapeutics, Inc.2 Alleviant Medical, Inc.2 Supernus Pharmaceuticals, Inc.2 Editas Medicine, Inc.2 Insulet Corporation2 Zenas BioPharma (USA), LLC2 Sebela Women's Health Inc.2 Syndeio Biosciences, Inc2 SuperPatch Limited LLC2 MBX Biosciences2 Orchestra BioMed, Inc2 Femasys Inc.2 Generate Biomedicines2 InGeneron, Inc.2 Medtronic Neurovascular Clinical Affairs2 Seaport Therapeutics2 Ascletis Pharma (China) Co., Limited2 Merit Medical Systems, Inc.2 Inhibrx Biosciences, Inc2 Pelage Pharmaceuticals, Inc.2 Akebia Therapeutics2 Axonics, Inc.2 Apogee Therapeutics, Inc.2 Medtronic MiniMed, Inc.2 Brixton Biosciences, Inc.2 Eccogene2 Artivion Inc.2 Relay Therapeutics, Inc.2 Nuvalent Inc.2 Stratpharma AG2 CG Oncology, Inc.2 CatalYm GmbH2 Phathom Pharmaceuticals, Inc.2 vTv Therapeutics2 Aclaris Therapeutics, Inc.2 Erasca, Inc.2 Hemab ApS2 Tenax Therapeutics, Inc.2 GIE Medical2 Pharming Technologies B.V.2 Altimmune, Inc.2 Viatris Innovation GmbH2 EyePoint Pharmaceuticals, Inc.2 Cook Research Incorporated2 RECORDATI GROUP2 MedImmune LLC2 Avalyn Pharma Inc.2 Sellas Life Sciences Group2 H. Lundbeck A/S2 Teva Branded Pharmaceutical Products R&D LLC2 Janssen Biotech, Inc.2 MoonLake Immunotherapeutics AG2 C. R. Bard2 Allogene Therapeutics2 CellCentric Ltd.2 ImmunoVaccine Technologies, Inc. (IMV Inc.)2 Dyne Therapeutics2 Alumis Inc2 Lineage Cell Therapeutics, Inc.2 DBV Technologies2 Palvella Therapeutics, Inc.2 Anthos Therapeutics, Inc.2 RayzeBio, Inc.2 Ocular Therapeutix, Inc.2 XVIVO Perfusion2 Penumbra Inc.2 Cybin IRL Limited2 Bio-Path Holdings, Inc.2 Cabaletta Bio2 Teligene US2 Endotronix, Inc.2 Servier Bio-Innovation LLC2 Bluefin Biomedicine, Inc.2 Mentor Worldwide, LLC2 Merz North America, Inc.2 Turning Point Therapeutics, Inc.2 Enveda Therapeutics2 Vaneltix Pharma, Inc.2 Liquidia Technologies, Inc.2 Lumos Pharma2 Otto Bock Healthcare Products GmbH2 Pierre Fabre Medicament2 Biosense Webster, Inc.2 Sangamo Therapeutics2 Medtronic Vascular2 Translational Sciences, Inc.2 MiRus2 Sun Pharmaceutical Industries Limited2 AskBio Inc2 Deciphera Pharmaceuticals, LLC2 Draig Therapeutics Ltd2 Impulse Dynamics2 Olema Oncology, Inc.2 Beam Therapeutics Inc.2 Target PharmaSolutions, Inc.2 Concept Medical Inc.2 Viridian Therapeutics, Inc.2 Nurix Therapeutics, Inc.2 Medtronic Cardiac Rhythm and Heart Failure2 Reunion Neuroscience Inc2 RAI Services Company2 Verismo Therapeutics2 DexCom, Inc.2 Autolus Limited2 Adverum Biotechnologies, Inc.2 Shionogi2 Daiichi Sankyo Co., Ltd.2 Noema Pharma AG2 Avidity Biosciences, Inc.2 Dren Bio2 Sana Biotechnology2 REGENXBIO Inc.2 Kura Oncology, Inc.2 Inari Medical2 Pyxis Oncology, Inc2 UniQure Biopharma B.V.2 Caribou Biosciences, Inc.2 Cogent Biosciences, Inc.2 Vega Therapeutics, Inc2 SetPoint Medical Corporation2 Merz Therapeutics GmbH2 TScan Therapeutics, Inc.2 GRAIL, Inc.2 TRiCares2 PROCEPT BioRobotics2 Albireo, an Ipsen Company2 Nkarta, Inc.2 CareDx2 SkylineDx2 SeaStar Medical2 Day One Biopharmaceuticals, Inc.2 Philips Clinical & Medical Affairs Global2 Ferring Pharmaceuticals2 Cullinan Therapeutics Inc.2 Longboard Pharmaceuticals2 Disc Medicine, Inc2 Inspire Medical Systems, Inc.2 Transcend Therapeutics2 Biomea Fusion Inc.2 HemoSonics LLC2 Electra Therapeutics Inc.2 Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics2 Verastem, Inc.2 VIVEX Biologics, Inc.2 Lyell Immunopharma, Inc.2 OncoC4, Inc.2 Oticon Medical1 Synchrony-Medical, Ltd1 Aspen Neuroscience1 Aragon Pharmaceuticals, Inc.1 CorMedix Therapeutics1 Angitia Biopharmaceuticals1 Capricor Inc.1 Appello Pharmaceuticals, Inc.1 Imbria Pharmaceuticals, Inc.1 HeartFlow, Inc.1 Amylyx Pharmaceuticals Inc.1 Insmed Gene Therapy LLC1 Optinose US Inc.1 ReGelTec, Inc.1 Mirador Therapeutics, Inc.1 Nammi Therapeutics Inc1 Kylonova (Xiamen) Biopharma co., LTD.1 Bactolife A/S1 TriReme Medical, LLC1 Outpace Bio, Inc.1 Kodiak Sciences Inc1 Cleerly, Inc.1 Akero Therapeutics, Inc1 X4 Pharmaceuticals1 Anika Therapeutics, Inc.1 SymBio Pharmaceuticals1 Shoulder Innovations1 ACADIA Pharmaceuticals Inc.1 Cordis US Corp.1 Wave Life Sciences USA, Inc.1 Cartography Biosciences1 Sparrow Pharmaceuticals1 CorDx, Inc.1 Jade Biosciences, Inc.1 Sundance Biosciences, Inc.1 CanariaBio Inc.1 Amplitude Vascular Systems, Inc.1 Endocrine Research Solutions1 Mesoblast, Ltd.1 Spineart USA1 inQB8 Medical Technologies, LLC1 Tenaya Therapeutics1 Tonix Pharmaceuticals, Inc.1 Nanobiotix1 Moleculin Biotech, Inc.1 Renibus Therapeutics, Inc.1 Thrombolex, Inc.1 Scholar Rock, Inc.1 Restore Biologics Holdings, Inc. dba Xtressé1 Acurx Pharmaceuticals Inc.1 River 2 Renal Corp.1 Heidelberg Pharma AG1 Artiva Biotherapeutics, Inc.1 ReAlta Life Sciences, Inc.1 Xcovery Holdings, Inc.1 Nipro Vascular Innovations Americas, Inc1 Asahi Kasei Therapeutics, AB1 MedRhythms, Inc.1 Soleno Therapeutics, Inc.1 Compugen Ltd1 Nexcella Inc.1 COMPASS Pathways1 Italfarmaco1 Caregen Co. Ltd.1 Spinal Simplicity LLC1 Cartesian Therapeutics1 Procyrion1 Marea Therapeutics1 LivaNova1 Climb Bio, Inc.1 Friendi.fi Corporation1 Anagram Therapeutics, Inc.1 Precigen, Inc1 Theradex1 Longeveron Inc.1 Biodesix, Inc.1 Luminopia1 Hansoh BioMedical R&D Company1 CathWorks Ltd.1 Puma Biotechnology, Inc.1 OriCell Therapeutics Co., Ltd.1 USWM CT, LLC1 GE Healthcare1 Aurinia Pharmaceuticals Inc.1 Tela Bio Inc1 CRISPR Therapeutics AG1 Rakuten Medical, Inc.1 Quetzal Therapeutics1 Valcare Medical Ltd.1 Helio Genomics1 Vifor Pharma, Inc.1 Kerecis Ltd.1 AtaCor Medical, Inc.1 Prilenia1 AnaptysBio, Inc.1 4C Medical Technologies, Inc.1 23andMe, Inc.1 Granata Bio Corporation1 PharmaJet, Inc.1 Vektor Medical1 Criterium, Inc.1 Bolt Medical1 Avenzo Therapeutics, Inc.1 phenox Inc.1 Protalix1 Valent Technologies, LLC1 Gossamer Bio USA, Inc.1 Inovio Pharmaceuticals1 ExThera Medical Corporation1 REVA Medical, Inc.1 Freenome Holdings Inc.1 CellTherX1 VIVUS LLC1 Primus Pharmaceuticals1 Vesalio1 Corxel Pharmaceuticals1 VisionCare, Inc.1 LeonaBio1 Inventiva Pharma1 Geneos Therapeutics1 Senseye, Inc.1 Immunome, Inc.1 BriaCell Therapeutics Corporation1 Supira Medical1 RAPT Therapeutics, Inc., a member of the GSK plc group of companies1 Iovance Biotherapeutics, Inc.1 Pathos AI, Inc.1 Aspira Women's Health1 Pharmacyclics Switzerland GmbH1 Imperative Care, Inc.1 Pharmazz, Inc.1 Gradalis, Inc.1 Adela, Inc1 V-Wave Ltd1 Skye Bioscience, Inc.1 Baxis Pharmaceuticals, Inc.1 Oruka Therapeutics, Inc.1 Eidos Therapeutics, a BridgeBio company1 Atavistik Bio, Inc1 Eledon Pharmaceuticals1 AiCuris Anti-infective Cures AG1 BioVentrix1 Polares Medical SA1 Elion Therapeutics, Inc.1 Bioverativ, a Sanofi company1 NMD Pharma A/S1 Chimeric Therapeutics1 Neuspera Medical, Inc.1 GigaGen, Inc.1 Black Diamond Therapeutics, Inc.1 eQ8Health Corporation d/b/a CareONE Concierge1 Nocion Therapeutics1 Cerium Pharmaceuticals, Inc.1 Trisol Medical1 Cook MyoSite1 Athos Therapeutics Inc1 Alcon Research1 Biotest1 Baxalta now part of Shire1 Photocure1 Epygenix1 Perelel Inc.1 CytoAgents, Inc.1 Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1 Anaconda Biomed S.L.1 Exactech1 Molecular Partners AG1 Acumen Pharmaceuticals1 Blue Lake Biotechnology Inc.1 CNS Pharmaceuticals, Inc.1 Regor Pharmaceuticals Inc.1 Alpha Cognition, Inc1 Zynerba Pharmaceuticals, Inc.1 Point Designs1 Volastra Therapeutics, Inc.1 PreludeDx1 Areteia Therapeutics1 Kyowa Kirin, Inc.1 Calixis Inc.1 Tioga Pharmaceuticals1 Magenta Medical Ltd.1 Paradigm Health1 Synthekine1 Greg Bew1 MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals1 Priothera SAS1 TVAX Biomedical1 Humacyte, Inc.1 Solid Biosciences Inc.1 Abbisko Therapeutics Co, Ltd1 ALX Oncology Inc.1 Philip Morris Products S.A.1 ProDa BioTech, LLC1 Invivyd, Inc.1 Saluda Medical Pty Ltd1 Alveus Therapeutics, Inc.1 Songqi Gao1 Newron Pharmaceuticals SPA1 Collagen Matrix1 Astellas Institute for Regenerative Medicine1 Tyra Biosciences, Inc1 Bracco Diagnostics, Inc1 Helius Medical Inc1 Laekna Limited1 Ranok Therapeutics (Hangzhou) Co., Ltd.1 Swedish Orphan Biovitrum1 Delfi Diagnostics Inc.1 Rigicon, Inc.1 Caris Science, Inc.1 Yarrow Bioscience, Inc.1 Maze Therapeutics1 TORL Biotherapeutics, LLC1 Motiva USA LLC1 VasoStar, LLC1 Fresenius Kabi1 Medtronic Spinal and Biologics1 Palette Life Sciences, Inc.1 Oxford Biodynamics Inc.1 Thrive Neuromedical, LLC1 Bodyport Inc.1 Averitas Pharma, Inc.1 Allarity Therapeutics1 CroiValve Limited1 Theravance Biopharma1 Lomond Therapeutics Holdings, Inc.1 HistoSonics, Inc.1 Daré Bioscience, Inc.1 Digital Health Navigation Solutions, Inc1 Stemline Therapeutics, Inc.1 MeiraGTx Ocular UK Ltd1 Endospan Ltd.1 Ambrx, Inc.1 Laplace Interventional, Inc1 Glaukos Corporation1 Biometry Inc1 Housey Healthcare ULC1 Laboratoires Thea1 Orthofix Inc.1 pharmaand GmbH1 Shape Memory Medical, Inc.1 TerSera Therapeutics LLC1 PolyNovo Biomaterials Pty Ltd.1 iECURE, Inc.1 BioXcel Therapeutics Inc1 Protara Therapeutics1 Hutchmed1 Head Diagnostics1 NewAmsterdam Pharma1 Autobahn Therapeutics, Inc.1 enGene, Inc.1 Spine BioPharma, Inc1 Immunocore Ltd1 KDH Research & Communication1 Neuron23 Inc.1 Zimmer Biomet1 Syntrix Biosystems, Inc.1 XyloCor Therapeutics, Inc.1 Hummingbird Diagnostics1 BetterMe Limited1 Compass Therapeutics1 Corvus Pharmaceuticals, Inc.1 Pramand LLC1 Uro-1 Medical1 Coologics, Inc1 Kardigan, Inc.1 Koneksa Health1 Nuvation Bio Inc.1 Elumn8 Medical1 Kyntra Bio1 Akeso1 Vedanta Biosciences, Inc.1 Evommune, Inc.1 Canary Medical1 Emmecell1 Vantage Biosciences Ltd1 NeuroPace1 BioAegis Therapeutics Inc.1 Ichnos Sciences SA1 Cognito Therapeutics, Inc.1 Alimera Sciences1 Empirical Spine, Inc.1 Dimerix Bioscience Pty Ltd1 Inquis Medical, Inc.1 ECRI bv1 Idorsia Pharmaceuticals Ltd.1 Splice Bio1 Kartos Therapeutics, Inc.1 BrainChild Bio, Inc1 AMAG Pharmaceuticals, Inc.1 AVEO Pharmaceuticals, Inc.1 Spyre Therapeutics, Inc.1 Genzyme, a Sanofi Company1 University Surgical Vascular1 Angiodynamics, Inc.1 Reviva Pharmaceuticals1 Miltenyi Biomedicine GmbH1 Biostar Pharma, Inc.1 Calico Life Sciences LLC1 Beijing Inno Medicine Co., Ltd.1 NorthSea Therapeutics B.V.1 Incyclix Bio1 OrthoTrophix, Inc1 Kiniksa Pharmaceuticals International, plc1 Apnimed1 Aravax Pty Ltd1 Organon and Co1 ITB-Med LLC1 Koning Corporation1 Buzzard Pharmaceuticals1 HighLife SAS1 Alpine Immune Sciences Inc, A Subsidiary of Vertex1 Currax Pharmaceuticals1 Mediar Therapeutics1 Hanmi Pharmaceutical Company Limited1 Hemanext1 OssDsign1 NextCure, Inc.1 Leal Therapeutics, Inc1 Aptinyx1 Arrowhead Pharmaceuticals1 Sun Pharmaceutical Industries, Inc.1 Lexicon Pharmaceuticals1 Forma Therapeutics, Inc.1 Prokidney1 Expedition Therapeutics, Inc1 Jina Pharmaceuticals Inc.1 Coya Therapeutics1 Uromedica1 Vor Biopharma1 Laminate Medical Technologies1 CG Pharmaceuticals, Inc1 Transcenta Therapeutics (Hangzhou) Co., Ltd.1 Medinol Ltd.1 Uniquity One (UNI)1 Biohaven Pharmaceuticals, Inc.1 EBR Systems, Inc.1 Zogenix, Inc.1 Mylan Pharmaceuticals Inc1 AriBio Co., Ltd.1 Mercator MedSystems, Inc.1 Bausch & Lomb Incorporated1 Eikon Therapeutics1 Apollo Therapeutics Ltd1 Harbinger Health1 Aptose Biosciences Inc.1 Senseonics, Inc.1 Aurion Biotech1 Astellas Gene Therapies1 Nectero Medical, Inc.1 Lighthouse Pharmaceuticals, Inc.1 Adneuris Therapeutics, Inc.1 NervGen Pharma1 ImStem Biotechnology1 Salubris Biotherapeutics Inc1 NeoChord1 Ensysce Biosciences1 Gravitas Medical, Inc.1 Astellas Pharma Inc1 Meryx, Inc.1 Cardiac Dimensions, Inc.1 Immuneering Corporation1 Stryker Endoscopy1 Genetix Biotherapeutics Inc.1 Neonc Technologies, Inc.1 OurRelationship1 Kelonia Therapeutics, Inc.1 K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc1 SightGlass Vision, Inc.1 Infant Bacterial Therapeutics1 Elicio Therapeutics1 ProMis Neurosciences, Inc1 Sumitomo Pharma Switzerland GmbH1 Beckman Coulter, Inc.1 Gentuity, LLC1 Ocugen1 Genelux Corporation1 Karyopharm Therapeutics Inc1 Companion IQ, Inc1 MediciNova1 Basilea Pharmaceutica1 Tectonic Therapeutic1 Aura Biosciences1 Clinuvel, Inc.1 i-SENS, Inc.1 Cellectar Biosciences, Inc.1 Epicrispr Biotechnologies, Inc.1 Integra LifeSciences Corporation1 Shanghai MicroPort Medical (Group) Co., Ltd.1 Pacira Pharmaceuticals, Inc1 K36 Therapeutics, Inc.1 Neuraptive Therapeutics Inc.1 Medicago1 DiaMedica Therapeutics Inc1 Immatics US, Inc.1 Kowa Research Institute, Inc.1 Aroa Biosurgery Limited1 YS Life Science Co., Ltd.1 Grace Therapeutics Inc.1 Retension Pharmaceuticals. Inc.1 Neurocrine Switzerland GmbH1 Emalex Biosciences Inc.1 Actelion1 Alpine Immune Sciences, Inc.1 Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)1 Poseida Therapeutics, Inc.1 Spur Therapeutics1 ABK Biomedical1 Altesa Biosciences, Inc.1 Royal Biologics1 EicOsis Human Health Inc.1 Ancora Heart, Inc.1 PharmaMar1 Upstream Bio Inc.1 Kymera Therapeutics, Inc.1 Serene Sleep, Inc.1 Cortex1 Piomic Medical1 Polyganics BV1 Janux Therapeutics1 Celcuity Inc1 R1 Therapeutics1 Abivax S.A.1 Beeline Medicines Corporation1 Priovant Therapeutics, Inc.1 Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.1 Colgate Palmolive1 PureTech1 Vogenx, Inc.1 Enliven Therapeutics1 Allotera Therapeutics1 Guided Therapeutics1 BrioHealth Solutions, Inc.1 Kardion Inc1 Salvia BioElectronics1 Reprieve Cardiovascular, Inc1 Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA1 SillaJen, Inc.1 Partner Therapeutics, Inc.1 ShiraTronics1 Johnson & Johnson Vision Care, Inc.1 ADC Therapeutics S.A.1 Asklepion Pharmaceuticals, LLC1 Endevica Bio1 Gedeon Richter Plc.1 Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1 Actinogen Medical1 NiKang Therapeutics, Inc.1 Mineralys Therapeutics Inc.1 Lipogems International spa1 Angel Medical Systems1 Emerald Clinical Inc.1 Praxis Precision Medicines1 Apifix1 Miach Orthopaedics1 Indaptus Therapeutics, Inc1 Vantive Health LLC1 Curonix LLC1 Neuren Pharmaceuticals Limited1 Tetra Discovery Partners1 Walden Biosciences1 Blue Earth Diagnostics1 Zura Bio Inc1 MBrace Therapeutics1 Blue Earth Therapeutics Ltd1 Arthroresearch LLC1 E-Star BioTech, LLC1 Pulmotect, Inc.1 Juno Therapeutics, a Subsidiary of Celgene1 atHeart Medical1 Medtronic - MITG1 Ultragenyx Pharmaceutical Inc1 PharmaEssentia1 Arga Medtech SA1 Endologix1 Ascendis Pharma A/S1 Axon Therapies, Inc.1 Fortis Medical Devices Limited1 PleoPharma, Inc.1 Antag Therapeutics1 Nyxoah S.A.1 Intellia Therapeutics1 Vividion Therapeutics, Inc.1 Kolon TissueGene, Inc.1 Rapport Therapeutics Inc.1 SAb Biotherapeutics, Inc.1 Ceek Women's Health, INC1 Savara Inc.1 InventisBio Co., Ltd1 BioInvent International AB1 Aspeya, Inc.1 Biosensors Europe SA1 Valencia Technologies Corporation1 BeiGene1 Renata Medical1 Kuros Biosurgery AG1 Devyser Inc.1 Morphic Medical Inc.1 DeepQure Inc.1 Acepodia Biotech, Inc.1 Trevi Therapeutics1 Oncolytics Biotech1 Fortvita Biologics (USA)Inc.1 Amneal Pharmaceuticals, LLC1 Voyager Therapeutics1 Greenwich LifeSciences, Inc.1 Minerva Neurosciences1 Coloplast A/S1 Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1 BioCardia, Inc.1 Annexon, Inc.1 Pliant Therapeutics, Inc.1 Caliway Biopharmaceuticals Co., Ltd.1 NeuroDerm Ltd.1 Shanghai Argo Biopharmaceutical Co., Ltd.1 Damora Therapeutics1 COUR Pharmaceutical Development Company, Inc.1 Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics1 Zucara Therapeutics Inc.1 EvolveImmune United, Inc1 Paragonix Technologies1 Ablative Solutions, Inc.1 NS Pharma, Inc.1 Indapta Therapeutics, INC.1 Vicore Pharma AB1 Immedica Pharma US Inc1 Avvio Medical1 Tarsus Pharmaceuticals, Inc.1 Energenesis Biomedical Co., Ltd.1 RapidPulse, Inc1 Respicardia, Inc.1 Corvia Medical1 Ossium Health, Inc.1 Axogen Corporation1 Imugene Limited1 Opna Bio LLC1 Ambros Therapeutics, Inc.1 BillionToOne Inc.1 ReCode Therapeutics1 Motif Neurotech, Inc.1 CarThera1 Myricx Pharma Limited1 ONWARD Medical, Inc.1 UCB BIOSCIENCES, Inc.1 Olatec Therapeutics, Inc.1 Neurotech Pharmaceuticals1 Ardelyx1 Medicenna Therapeutics, Inc.1 Q32 Bio Inc.1 ZimVie1 Alebund Pharmaceuticals1 Sumitomo Pharma America, Inc.1 Delve Bio, Inc.1 Spark Therapeutics, Inc.1 Cerevance1 Bavarian Nordic1 Lipocine Inc.1 JC Medical, Inc., an affiliate of Edwards Lifesciences LLC1 Sirtex Medical1 OncoTherapy Science, Inc.1
Target enrolment
to

Trials with a site in Georgia

2364 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Missouri
2027-11-23
Not yet open
HemoSonics LLC
Observational
160
California, Georgia, Pennsylvania
2027-06-25
Not yet open
HemoSonics LLC
Observational
240
California, Georgia, Massachusetts
2027-03-15
Not yet open
Boehringer Ingelheim
Phase 3
1,800
Alabama, Arizona, California, Florida, Georgia, Illinois, Massachusetts, Missouri
2027-03-10
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Arizona, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2027-02-03
Not yet open
Boehringer Ingelheim
Phase 3
1,500
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2027-01-11
Recruiting
A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs
NCT07905183Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML
Enliven Therapeutics
Phase 3
450
Georgia, Indiana, New Jersey, Utah
2026-12-31
Recruiting
Idorsia Pharmaceuticals Ltd.
Phase 3
16
Alabama, California, Florida, Georgia, Illinois, Minnesota, Pennsylvania, Texas
2026-12-01
Recruiting
A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
NCT07719608Resistant Migraine, Chronic Migraine Headache, Headache (Migraine), Headache, Cluster
Salvia BioElectronics
Not applicable
150
Georgia, Maryland, North Carolina
2026-12-01
Not yet open
Eli Lilly and Company
Phase 3
2,115
Arizona, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana
2026-12
Not yet open
Eli Lilly and Company
Phase 2
120
California, Colorado, Georgia, Massachusetts, Ohio, Texas, Virginia
2026-12
Recruiting
Jade Biosciences, Inc.
Phase 3
480
Colorado, Florida, Georgia, Texas
2026-12
Not yet open
Long Term Safety Study in Patients With HLH/MAS in Still's Disease Exposed to Gamifant.
NCT07909005Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Still Disease
Swedish Orphan Biovitrum
Observational
70
Alabama, California, Florida, Georgia, Massachusetts, Michigan, Minnesota, New York
2026-12
Not yet open
Eli Lilly and Company
Phase 3
3,000
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Illinois
2026-12
Recruiting
Hoffmann-La Roche
Phase 2
40
California, District of Columbia, Georgia, Nebraska, New York, Tennessee, West Virginia
2026-11-30
Not yet open
Bayer
Observational
2,400
Alabama, Arkansas, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts
2026-11-30
Not yet open
AstraZeneca
Phase 2
250
California, Colorado, Connecticut, Florida, Georgia, Illinois, South Carolina, Texas
2026-11-30
Not yet open
Hypoxic Red Blood Cells in Sickle Cell Anemia
NCT06743113Sickle Cell Anaemia, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Hemanext
Not applicable
48
Connecticut, Georgia, Illinois, Maryland, Pennsylvania
2026-11-30
Recruiting
Boehringer Ingelheim
Phase 3
350
California, Florida, Georgia, Louisiana, Maryland, North Carolina, Utah
2026-11-25
Recruiting
Boehringer Ingelheim
Phase 3
600
Alabama, California, Florida, Georgia, Louisiana, Maryland, North Carolina, Utah
2026-11-25
Not yet open
Annovis Bio Inc.
Phase 2/3
400
Colorado, Florida, Georgia, New Jersey, North Carolina, Texas, Virginia
2026-11-21
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 3
40
Florida, Georgia
2026-11-13
Recruiting
Novartis Pharmaceuticals
Phase 3
340
Alabama, California, Delaware, Florida, Georgia, Nevada, Virginia
2026-11-11
Not yet open
Novo Nordisk A/S
Phase 3
1,408
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky
2026-11-11
Recruiting
Pelage Pharmaceuticals, Inc.
Phase 2
200
Arkansas, Georgia, New York, South Carolina, Tennessee, Texas
2026-11-10
Recruiting
Eli Lilly and Company
Phase 2
330
California, Florida, Georgia, Massachusetts, Nevada, New Jersey, New York, Pennsylvania
2026-11-10
Recruiting
Boehringer Ingelheim
Phase 1
90
Florida, Georgia, Pennsylvania, Tennessee, Texas
2026-11-10
Recruiting
Caliway Biopharmaceuticals Co., Ltd.
Phase 3
320
California, Florida, Georgia, Louisiana, Maryland, Nebraska, New York, Ohio
2026-11-09
Recruiting
Merck Sharp & Dohme LLC
Phase 2
380
Florida, Georgia, Illinois, Texas, Utah
2026-11-02
Not yet open
Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test
NCT07875270SARS-CoV-2 Infection, Influenza A, Influenza B, RSV
CorDx, Inc.
Not applicable
1,500
Georgia
2026-11-01
Recruiting
Viking Therapeutics, Inc.
Phase 3
560
Arizona, California, Florida, Georgia, Indiana, Minnesota, Mississippi, Missouri
2026-11
Recruiting
Aclaris Therapeutics, Inc.
Phase 2
102
Georgia, Minnesota
2026-11
Recruiting
SystImmune Inc.
Phase 3
520
Georgia, Hawaii, Virginia
2026-11
Recruiting
Viking Therapeutics, Inc.
Phase 3
560
Arizona, California, Florida, Georgia, Indiana, Kentucky, Minnesota, Mississippi
2026-11
Recruiting
Bristol-Myers Squibb
Phase 2
200
Arizona, Arkansas, California, Florida, Georgia, Maryland, New York, Ohio
2026-10-30
Recruiting
Kowa Research Institute, Inc.
Not applicable
340
California, Colorado, Georgia, Missouri, South Carolina, Texas, Virginia
2026-10-30
Not yet open
Smith & Nephew, Inc.
Not applicable
330
Colorado, Georgia, Indiana
2026-10-30
Recruiting
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
NCT07228442Locally Advanced Cutaneous Squamous Cell Carcinoma
Philogen S.p.A.
Phase 2
92
California, Georgia, Massachusetts, North Carolina, Ohio, Texas
2026-10-29
Not yet open
Pfizer
Phase 3
750
Arizona, California, Florida, Georgia, Idaho, Oregon, Tennessee, Texas
2026-10-29
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-10-26
Recruiting
Pfizer
Phase 3
656
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Louisiana
2026-10-26
Recruiting
Eli Lilly and Company
Phase 1
617
Arkansas, California, Florida, Georgia, Missouri, New Jersey, Ohio, Texas
2026-10-22
Recruiting
TerSera Therapeutics LLC
Phase 1
176
Arkansas, District of Columbia, Florida, Georgia, Illinois, Iowa, Louisiana, Michigan
2026-10-20
Recruiting
Vogenx, Inc.
Phase 2
36
California, Colorado, Florida, Georgia, North Carolina, Pennsylvania, Tennessee, Texas
2026-10-20
Recruiting
Eli Lilly and Company
Phase 3
1,000
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Indiana
2026-10-16
Recruiting
Amgen
Phase 3
230
California, Florida, Georgia, Idaho, Illinois, Maryland, New York, North Carolina
2026-10-15
Not yet open
Cullinan Therapeutics Inc.
Phase 1
90
California, Florida, Georgia, New York, Texas
2026-10-15
Recruiting
Jazz Pharmaceuticals
Phase 2
50
California, Florida, Georgia, Kentucky, Missouri, South Carolina
2026-10-12
Recruiting
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
NCT07787182Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Eli Lilly and Company
Phase 1
68
California, Florida, Georgia, Michigan
2026-10-10
Not yet open
Lumos Pharma
Phase 1
30
Georgia
2026-10-08
Recruiting
AbbVie
Phase 2
300
Alabama, Arizona, California, Connecticut, District of Columbia, Georgia, Indiana, Louisiana
2026-10-08
Recruiting
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
NCT07843459Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Eli Lilly and Company
Phase 1
111
California, Florida, Georgia, Michigan
2026-10-07
Recruiting
Novartis Pharmaceuticals
Phase 3
180
California, Florida, Georgia, Massachusetts, Michigan, Ohio, Texas
2026-10-07
Recruiting
Bristol-Myers Squibb
Phase 3
176
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2026-10-06
Recruiting
Hoffmann-La Roche
Phase 3
400
California, Florida, Georgia, Massachusetts, Michigan, Nevada, New Mexico, Ohio
2026-10-06
Recruiting
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
NCT07284745Irritability Associated With Autism Spectrum Disorder
Bristol-Myers Squibb
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2026-10-06
Recruiting
Spyre Therapeutics, Inc.
Phase 2
150
Alabama, Arkansas, California, Florida, Georgia, Indiana, Kentucky, Louisiana
2026-10-06
Recruiting
Medtronic MiniMed, Inc.
Not applicable
1,500
California, Colorado, Connecticut, Florida, Georgia, Idaho, Texas, Virginia
2026-10-05
Recruiting
AiCuris Anti-infective Cures AG
Phase 2
24
Alabama, California, Florida, Georgia, Illinois, Maryland, Missouri, New Jersey
2026-10-05
Recruiting
Hoffmann-La Roche
Phase 3
1,600
California, Florida, Georgia, Hawaii, Illinois, Massachusetts, New York, Virginia
2026-10-02
Recruiting
TriGemX Bio, Inc.
Phase 3
1,500
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2026-10-02
Recruiting
Motif Neurotech, Inc.
Not applicable
20
Georgia, Iowa, Texas
2026-10-02
Recruiting
Gilead Sciences
Phase 2
132
Colorado, Florida, Georgia, Tennessee
2026-10-01
Active, closed
Sanofi
Phase 4
669
California, Florida, Georgia, Illinois, Iowa, Kansas, Louisiana, Maryland
2026-10-01
Recruiting
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
NCT07840326Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS)
Sundance Biosciences, Inc.
Phase 2
20
Florida, Georgia, New York, North Carolina, Ohio, Oklahoma, Texas
2026-10
Recruiting
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
NCT07729137Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
Emmecell
Phase 2
121
California, Florida, Georgia, Illinois, Indiana, Kansas, Minnesota, Missouri
2026-10
Not yet open
Validation of cueStim for Reduction of Freezing of Gait in Parkinson's Disease
NCT07675408Parkinson's Disease With Freezing of Gait
Fortis Medical Devices Limited
Not applicable
60
Florida, Georgia, Kansas, Oregon, Washington
2026-10
Recruiting
Flutemetamol F 18 Injection Formulation Comparison
NCT07873463Cognitive Dysfunction
GE Healthcare
Phase 2
20
Florida, Georgia
2026-09-30
Recruiting
RAI Services Company
Not applicable
480
Florida, Georgia, Illinois, New Jersey, Texas
2026-09-30
Recruiting
Fortvita Biologics (USA)Inc.
Phase 1/2
360
Arizona, California, Georgia, New York, Texas
2026-09-30
Recruiting
vTv Therapeutics
Phase 2
40
California, Colorado, Georgia, North Carolina, Texas
2026-09-29
Recruiting
Novartis Pharmaceuticals
Phase 2
259
Alabama, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2026-09-29
Recruiting
Philogen S.p.A.
Phase 2
180
Florida, Georgia, North Carolina, Ohio, Texas
2026-09-28
By invitation
Head Diagnostics
Observational
120
Georgia, Massachusetts
2026-09-28
Recruiting
NervGen Pharma
Phase 3
150
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-09-28
Recruiting
Acurx Pharmaceuticals Inc.
Phase 2
20
California, Connecticut, Florida, Georgia, Idaho, Illinois, Massachusetts, Michigan
2026-09-25
Recruiting
Eli Lilly and Company
Phase 3
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2026-09-25
Recruiting
Phathom Pharmaceuticals, Inc.
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Idaho, Nevada, New York
2026-09-25
Recruiting
Transcend Therapeutics
Phase 3
300
Colorado, Florida, Georgia, New Jersey, Utah
2026-09-25
Recruiting
Agios Pharmaceuticals, Inc.
Phase 3
54
Georgia, New York, Pennsylvania, Texas
2026-09-24
Recruiting
AstraZeneca
Phase 3
750
Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky, Massachusetts
2026-09-24
Recruiting
Novo Nordisk A/S
Phase 3
650
California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana, Missouri
2026-09-22
Recruiting
Adneuris Therapeutics, Inc.
Phase 3
160
Arizona, California, Colorado, Georgia, Illinois, Maryland, New Jersey, Oklahoma
2026-09-22
Recruiting
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
NCT07819435Androgenetic Alopecia
DrugPP405
Pelage Pharmaceuticals, Inc.
Phase 2/3
600
Alabama, Arkansas, California, Florida, Georgia, Idaho, Indiana, Kentucky
2026-09-21
Recruiting
Jazz Pharmaceuticals
Phase 2/3
260
Arizona, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2026-09-18
By invitation
Sanofi
Phase 3
1,508
California, Florida, Georgia
2026-09-16
Recruiting
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
NCT07766499Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
Calixis Inc.
Phase 2
81
California, Florida, Georgia, Idaho, Louisiana, Maryland, Missouri, North Carolina
2026-09-15
Recruiting
Vima Therapeutics
Phase 2
80
Arizona, California, Connecticut, Florida, Georgia, Kansas, Maryland, Michigan
2026-09-15
Not yet open
Enamel Lesion Detection With New DX Tool
NCT07819370Enamel Lesions, Caries
Colgate Palmolive
Phase 4
5
Georgia
2026-09-15
Recruiting
WATER IV PCa (AS Sub-study)
NCT07650448Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
333
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2026-09-11
Recruiting
Medtronic Cardiovascular
Not applicable
1,186
Alabama, Arizona, California, Connecticut, Georgia, Illinois, Kansas, Minnesota
2026-09-11
Recruiting
Bristol-Myers Squibb
Phase 2
160
District of Columbia, Georgia, Kentucky, Maryland, Mississippi, Nebraska, New York, Ohio
2026-09-10
Recruiting
AstraZeneca
Phase 3
200
Arizona, California, Florida, Georgia, Indiana, Louisiana, Maryland, North Carolina
2026-09-10
Recruiting
Takeda
Phase 3
324
Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Michigan, Missouri
2026-09-10
Recruiting
Johnson & Johnson Vision Care, Inc.
Not applicable
150
Florida, Georgia, Missouri, New York, Rhode Island, Tennessee, Texas, Virginia
2026-09-10
Recruiting
Eli Lilly and Company
Phase 1
179
California, Florida, Georgia, Michigan
2026-09-09
Active, closed
Pfizer
Phase 3
4,701
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Iowa
2026-09-08
Recruiting
Regeneron Pharmaceuticals
Phase 1
36
Georgia, New Jersey, Oregon
2026-09-08
Recruiting
Digital STEADI Efficacy
NCT07852650Fall, Mild Cognitive Impairment (MCI), Aging
Friendi.fi Corporation
Phase 1/2
300
Georgia
2026-09-04
Recruiting
BrainChild Bio, Inc
Phase 2
75
California, Georgia, Illinois, Ohio, Pennsylvania, Washington
2026-09-04
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 4
180
California, Florida, Georgia
2026-09-03
Recruiting
Kyowa Kirin, Inc.
Phase 1
72
California, Florida, Georgia, Iowa, Massachusetts, Missouri, New Jersey, New York
2026-09-02
Recruiting
GlaxoSmithKline
Phase 3
54,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-09-02
Recruiting
Genentech, Inc.
Phase 4
100
Alabama, Arizona, Colorado, Florida, Georgia, Tennessee
2026-09-02
Recruiting
Polares Medical SA
Not applicable
15
Georgia, New York, Ohio
2026-09-01
Recruiting
AstraZeneca
Phase 3
2,800
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2026-09-01
Recruiting
Geneos Therapeutics
Phase 2
90
Georgia, Louisiana, Maryland, Michigan, New York, Texas, Washington
2026-09
Recruiting
L19IL2/TNF in Patients With Basal Cell Carcinoma
NCT07227870Locally Advanced Basal Cell Carcinoma
Philogen S.p.A.
Phase 2
92
Florida, Georgia, New York, Ohio, Texas
2026-09
Recruiting
Liquidia Technologies, Inc.
Phase 4
20
Georgia
2026-09
Recruiting
Agios Pharmaceuticals, Inc.
Phase 3
45
California, Georgia, New York, Pennsylvania, Texas
2026-09
Recruiting
Vaginal Wall Retraction Using VuSleeve
NCT07846527Adult Females
Ceek Women's Health, INC
Observational
500
Colorado, Georgia
2026-09
Recruiting
Damora Therapeutics
Phase 1
250
Alabama, Arizona, California, Florida, Georgia, Kansas, Maryland, Massachusetts
2026-09
Recruiting
Brexanolone Lifting Outcomes Of Moms
NCT07822321Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression
Lipocine Inc.
Phase 3
120
Arizona, California, Colorado, Georgia, Idaho, Illinois, Louisiana, Nevada
2026-09
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2026-08-31
Active, closed
BioNTech SE
Phase 3
713
Florida, Georgia, Hawaii, Kentucky, Maryland, Ohio, Pennsylvania, Texas
2026-08-31
Recruiting
Novo Nordisk A/S
Phase 3
950
Alabama, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana
2026-08-31
Recruiting
Pfizer
Phase 3
440
California, Colorado, District of Columbia, Georgia, Iowa, Louisiana, Maryland, Missouri
2026-08-31
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2026-08-28
Recruiting
Eli Lilly and Company
Phase 2
120
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2026-08-27
Recruiting
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
NCT07768371IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
Novartis Pharmaceuticals
Phase 3
576
Alabama, Arizona, Arkansas, California, Colorado, Georgia, Illinois, Maryland
2026-08-27
Recruiting
Axsome Therapeutics, Inc.
Phase 3
705
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Missouri
2026-08-27
Recruiting
MBX Biosciences
Phase 3
160
California, Colorado, Florida, Georgia, Louisiana, Mississippi, Nebraska, Nevada
2026-08-26
Recruiting
Pfizer
Phase 3
400
Arizona, California, Florida, Georgia, Indiana, Kansas, Massachusetts, Michigan
2026-08-26
Recruiting
Eli Lilly and Company
Phase 3
2,001
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-08-26
Recruiting
Novartis Pharmaceuticals
Phase 3
180
Alabama, Florida, Georgia, Indiana, New York, Ohio, Pennsylvania, South Carolina
2026-08-24
Recruiting
Boehringer Ingelheim
Phase 3
600
Alabama, Arizona, Arkansas, California, Florida, Georgia, Hawaii, Idaho
2026-08-24
Recruiting
Pfizer
Phase 3
1,375
Alabama, Arizona, Arkansas, California, Florida, Georgia, Idaho, Indiana
2026-08-24
Recruiting
AstraZeneca
Phase 3
500
California, Florida, Georgia, Illinois, Maryland, Missouri, Nevada, New Jersey
2026-08-24
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
AstraZeneca
Phase 3
6,950
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-08-21
Recruiting
Oruka Therapeutics, Inc.
Phase 2
200
Alabama, California, Connecticut, Georgia, Illinois, Indiana, Louisiana, Michigan
2026-08-21
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
472
Arkansas, California, Florida, Georgia, Illinois, Maryland, Ohio, Oklahoma
2026-08-20
Recruiting
AstraZeneca
Phase 3
1,500
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Iowa
2026-08-20
Recruiting
AstraZeneca
Phase 3
2,500
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Iowa
2026-08-19
Active, closed
Bausch Health Americas, Inc.
Phase 2
180
Alabama, Arkansas, California, Florida, Georgia, Kansas, Louisiana, Maryland
2026-08-18
Recruiting
Pfizer
Phase 3
375
Alabama, Arizona, California, Florida, Georgia, North Dakota, Texas
2026-08-17
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes
NCT07712562Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse
Dren Bio
Phase 1/2
60
California, Florida, Georgia, New York, Ohio, Texas, Virginia, Washington
2026-08-14
Recruiting
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-08-14
Recruiting
Alkermes, Inc.
Phase 3
150
Arizona, Florida, Georgia, Kansas, Michigan, Minnesota, Missouri, New York
2026-08-13
Recruiting
AstraZeneca
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-08-12
Recruiting
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-08-12
Recruiting
Genmab
Phase 3
960
Arkansas, California, Georgia, Indiana, Missouri, New York, Washington
2026-08-11
Recruiting
Alveus Therapeutics, Inc.
Phase 2
220
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan
2026-08-10
Recruiting
Regeneron Pharmaceuticals
Phase 3
15,364
Alabama, Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana
2026-08-10
Recruiting
Alkermes, Inc.
Phase 2
312
Arkansas, California, Florida, Georgia, Massachusetts, Michigan, Nebraska, Nevada
2026-08-10
Recruiting
Nektar Therapeutics
Phase 3
510
Alabama, California, Florida, Georgia, Louisiana, Missouri, Nevada, New Jersey
2026-08-07
Recruiting
Novo Nordisk A/S
Phase 3
80
Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, New York
2026-08-04
Recruiting
AbbVie
Phase 2
360
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Kentucky
2026-08-04
Recruiting
Novo Nordisk A/S
Phase 3
285
Georgia, Hawaii, Illinois, Indiana, Kentucky, North Carolina, South Carolina, Virginia
2026-08-04
Recruiting
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Nurix Therapeutics, Inc.
Phase 3
620
Georgia, Indiana, Tennessee, Texas, Virginia
2026-08-03
Recruiting
TriGemX Bio, Inc.
Phase 3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois
2026-08-03
Recruiting
Leal Therapeutics, Inc
Phase 1
90
Arkansas, California, Florida, Georgia, Maryland, New Jersey, Texas
2026-08-03
Recruiting
Sanofi
Phase 1/2
640
Arizona, California, Florida, Georgia, Illinois, Kansas, New York, South Carolina
2026-08-03
Recruiting
VETERANS AFFAIRS AUGUSTA
NCT07776600Chronic Pain
Companion IQ, Inc
Not applicable
200
Georgia
2026-08-01
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007Atherosclerosis, Coronary Artery Disease
Beijing Inno Medicine Co., Ltd.
Phase 2
456
Alabama, California, Florida, Georgia, Idaho, Illinois, Kansas, Missouri
2026-07-31
Recruiting
AbbVie
Phase 2
2,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-07-31
Recruiting
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
NCT07575308Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
Alnylam Pharmaceuticals
Phase 2
24
California, Florida, Georgia, Kentucky, North Carolina, Ohio, Pennsylvania, South Carolina
2026-07-30
Recruiting
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
NCT07795164Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Altimmune, Inc.
Phase 3
1,800
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana
2026-07-30
Recruiting
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
NCT06419205IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
Akebia Therapeutics
Phase 2
30
Florida, Georgia, South Carolina
2026-07-30
Recruiting
Evommune, Inc.
Phase 2
330
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2026-07-29
Recruiting
Gilead Sciences
Phase 2/3
700
California, Connecticut, Florida, Georgia, Missouri, New Jersey, Texas, Washington
2026-07-29
Recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
576
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Louisiana
2026-07-28
Recruiting
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07601425Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Atavistik Bio, Inc
Phase 1/2
100
Arizona, California, Georgia, Indiana, Massachusetts, Minnesota, Missouri, North Carolina
2026-07-27
Recruiting
AstraZeneca
Phase 1/2
101
California, Colorado, Florida, Georgia, Missouri, New Jersey, Ohio, Tennessee
2026-07-27
Recruiting
UCB Biopharma SRL
Phase 2
402
California, Florida, Georgia, North Carolina, Ohio, Oregon, Pennsylvania, South Carolina
2026-07-27
Recruiting
ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain
NCT07568015Greater Trochanteric Pain Syndrome, Greater Trochanteric Pain Syndrome of Both Lower Limbs, Lateral Hip Pain
Brixton Biosciences, Inc.
Not applicable
100
Arizona, Georgia, Louisiana, Massachusetts, New Jersey, Oklahoma, Pennsylvania, Texas
2026-07-27
Recruiting
Bristol-Myers Squibb
Phase 2
254
California, Colorado, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New York
2026-07-27
Recruiting
Janssen Research & Development, LLC
Phase 3
348
California, Connecticut, Florida, Georgia, Idaho, Illinois, Massachusetts, New York
2026-07-23
Recruiting
Amgen
Phase 3
3,200
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2026-07-23
Recruiting
Gilead Sciences
Phase 1
112
California, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Nevada, New Jersey
2026-07-22
Recruiting
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
NCT07734649Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Sanofi
Phase 1/2
2,400
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana
2026-07-22
Recruiting
Verastem, Inc.
Phase 2
105
Arizona, California, Colorado, Florida, Georgia, Illinois, New Jersey, New York
2026-07-22
Recruiting
Bayer
Observational
300
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-07-21
Recruiting
VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)
NCT07390344Ascites, Variceal Bleeding, Portal Hypertension Related to Cirrhosis
W.L.Gore & Associates
Observational
152
Georgia, Minnesota, Ohio, Texas
2026-07-20
Recruiting
A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3
NCT07807241Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
Myricx Pharma Limited
Phase 1
120
Florida, Georgia, Maryland, Texas, Virginia
2026-07-20
Recruiting
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
1,100
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2026-07-17
Recruiting
Gilead Sciences
Phase 3
850
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2026-07-14
Recruiting
UCB BIOSCIENCES, Inc.
Phase 3
200
Arkansas, Florida, Georgia, Pennsylvania, Texas, Washington
2026-07-14
Recruiting
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
3,600
Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois
2026-07-13
Recruiting
Boehringer Ingelheim
Phase 3
390
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota
2026-07-10
Recruiting
Jazz Pharmaceuticals
Phase 3
120
Alabama, California, Colorado, Delaware, Florida, Georgia, Maryland, Michigan
2026-07-09
Recruiting
AstraZeneca
Phase 3
600
Arkansas, California, Colorado, Florida, Georgia, Maryland, New York, North Carolina
2026-07-08
Recruiting
Eli Lilly and Company
Phase 3
170
California, Connecticut, Georgia, Idaho, Kansas, New York, Oklahoma, Pennsylvania
2026-07-08
Recruiting
The TRICURE US IDE Pivotal Study
NCT07528326Tricuspid Regurgitation (TR)
TRiCares
Not applicable
831
Georgia
2026-07-08
Not yet open
Measuring Knee Laxity and Pivot Shift in ACL-Deficient Patients
NCT07688967Anterior Cruciate Ligament (ACL) Tear
Arthroresearch LLC
Observational
25
Georgia
2026-07-07
Recruiting
Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
NCT07575269Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fibrillation
Boston Scientific Corporation
Not applicable
571
Arkansas, Georgia, Iowa, Massachusetts, New York, Ohio, Pennsylvania, South Carolina
2026-07-07
Recruiting
AstraZeneca
Phase 3
1,200
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-07-06
Recruiting
Axsome Therapeutics, Inc.
Phase 3
468
Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Mississippi
2026-07-06
Recruiting
AstraZeneca
Phase 3
800
Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Kentucky
2026-07-06
Recruiting
AstraZeneca
Phase 3
2,000
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa
2026-07-06
Active, closed
Intuitive Surgical
Not applicable
30
Georgia, New York, Washington
2026-07-06
Recruiting
Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study
NCT07324031Ventricular Arrythmia, Ventricular Fibrillation, Ventricular Tachycardia
AtaCor Medical, Inc.
Not applicable
280
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kentucky
2026-07-02
Recruiting
AbbVie
Phase 3
531
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-07-02
Recruiting
TriGemX Bio, Inc.
Phase 3
1,800
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois
2026-07-01
Recruiting
Pfizer
Phase 1
120
Colorado, Connecticut, Florida, Georgia, Ohio, Tennessee
2026-07-01
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
272
California, Colorado, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts
2026-07-01
Recruiting
Neurocrine Switzerland GmbH
Phase 2
20
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Michigan, Minnesota
2026-07-01
Not yet open
Shockwave Medical, Inc.
Not applicable
185
Arizona, Colorado, Florida, Georgia, Louisiana, Missouri, New York, North Carolina
2026-07
Recruiting
A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
NCT07664735Endometrial Cancer Recurrent, Endometrial Cancer, Advanced Endometrial Cancer, Ovarian Cancer
Outpace Bio, Inc.
Phase 1
30
California, Georgia, Michigan, Minnesota, Texas
2026-06-30
Recruiting
Pfizer
Phase 2
120
Alabama, California, Georgia, Illinois, Massachusetts, Nebraska, New Mexico, Tennessee
2026-06-30
Active, closed
Boehringer Ingelheim
Phase 2
345
Alabama, California, Florida, Georgia, Kentucky, Michigan, Missouri, North Carolina
2026-06-30
Recruiting
Expedition Therapeutics, Inc
Phase 2
600
Arizona, California, Colorado, Florida, Georgia, Indiana, Kansas, Louisiana
2026-06-30
Recruiting
AstraZeneca
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-06-29
Recruiting
Nektar Therapeutics
Phase 3
510
Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Kentucky
2026-06-29
Recruiting
ITB-Med LLC
Phase 2
120
California, Florida, Georgia, Kansas, Kentucky, Louisiana, Massachusetts, Michigan
2026-06-29
Recruiting
Trevi Therapeutics
Phase 3
306
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Minnesota, Missouri
2026-06-29
Recruiting
Biohaven Therapeutics Ltd.
Phase 3
300
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana
2026-06-26
Recruiting
AstraZeneca
Phase 3
750
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2026-06-26
Recruiting
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
NCT07621237Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
Tonix Pharmaceuticals, Inc.
Phase 2
360
Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts
2026-06-25
Recruiting
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-06-25
Recruiting
Axsome Therapeutics, Inc.
Phase 3
468
Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Mississippi
2026-06-25
Recruiting
ViiV Healthcare
Phase 3
564
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland
2026-06-25
Recruiting
Hoffmann-La Roche
Phase 3
380
California, Connecticut, District of Columbia, Georgia, Illinois, North Carolina, Ohio, Pennsylvania
2026-06-23
Recruiting
Cordis US Corp.
Observational
35
California, Georgia, Michigan, Missouri, Nebraska, Ohio, Pennsylvania, Texas
2026-06-23
Recruiting
Intervention to Help Orient Men to Excel (IN-HOME) Phase II Study
NCT07704060Caregivers, Community Health Workers, Knowledge, Attitude
KDH Research & Communication
Not applicable
360
Georgia
2026-06-19
Active, closed
Antag Therapeutics
Phase 2
150
Arizona, California, Florida, Georgia, Utah
2026-06-19
Active, closed
TScan Therapeutics, Inc.
Phase 3
310
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2026-06-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Georgia, Illinois, Nebraska, New Jersey, New York, North Carolina, Virginia
2026-06-18
Active, closed
Regeneron Pharmaceuticals
Phase 2
438
Alabama, California, Florida, Georgia, Hawaii, Kentucky, Louisiana, Montana
2026-06-17
By invitation
Serene Sleep, Inc.
Not applicable
26
California, Georgia
2026-06-17
Recruiting
PleoPharma, Inc.
Phase 3
420
Arkansas, Connecticut, Florida, Georgia, Kentucky, Maryland, Nevada, New Jersey
2026-06-17
Recruiting
AstraZeneca
Phase 3
150
California, Georgia, Illinois, Kentucky, Nevada, South Dakota, Tennessee, Texas
2026-06-15
Recruiting
Gilead Sciences
Phase 2
175
Arizona, California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey
2026-06-15
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-06-11
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
Takeda
Phase 2/3
500
California, Colorado, Florida, Georgia, Maryland, Michigan, Missouri, New Jersey
2026-06-11
Recruiting
Yarrow Bioscience, Inc.
Phase 2
232
Arizona, California, Florida, Georgia, Kentucky, Michigan, Nebraska, New York
2026-06-10
Recruiting
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
NCT07504458Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Quetzal Therapeutics
Phase 3
150
Alabama, California, Colorado, Georgia, Kentucky, Maryland, Michigan, New York
2026-06-08
Recruiting
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
NCT07484022Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
Generate Biomedicines
Phase 1
37
California, Florida, Georgia, Illinois, New Jersey, New York, Texas, Virginia
2026-06-08
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Immuneering Corporation
Phase 3
570
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2026-06-05
Recruiting
GlaxoSmithKline
Phase 1/2
1,456
Georgia, Kansas, Washington
2026-06-05
Recruiting
Rapport Therapeutics Inc.
Phase 3
333
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Maryland
2026-06-05
Recruiting
Harmony Biosciences Management, Inc.
Phase 3
258
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-06-04
Recruiting
Galderma R&D
Not applicable
100
Connecticut, Florida, Georgia, Maryland, Tennessee, Texas
2026-06-03
Recruiting
InventisBio Co., Ltd
Phase 2
75
Alabama, Arizona, California, Florida, Georgia, Idaho, Indiana, Kentucky
2026-06-03
Recruiting
YS Life Science Co., Ltd.
Phase 3
600
California, Florida, Georgia, Kentucky, Missouri, Texas
2026-06-02
Not yet open
Evaluation of the Efficacy, Safety, and Tolerability of LevoCept
NCT04457076Contraception, Women at Risk for Pregnancy
Sebela Women's Health Inc.
Phase 3
1,525
California, Colorado, Georgia, Hawaii, Indiana, Minnesota, Missouri, Nevada
2026-06-01
Recruiting
Bayer
Phase 3
117
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2026-06-01
Active, closed
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
NCT06712654Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
R1 Therapeutics
Phase 2
168
Alabama, California, Colorado, Connecticut, Florida, Georgia, Michigan, Minnesota
2026-06-01
Recruiting
AbbVie
Phase 2/3
576
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maine
2026-06-01
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-31
Recruiting
Novo Nordisk A/S
Phase 1
114
California, Florida, Georgia, North Carolina, South Carolina, Tennessee, Texas
2026-05-29
Recruiting
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
NCT07480356Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Protara Therapeutics
Phase 3
284
Arizona, Arkansas, California, Georgia, Missouri, South Carolina, Texas
2026-05-29
Recruiting
Novartis Pharmaceuticals
Phase 2
120
Alabama, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-29
Recruiting
Centessa Pharmaceuticals (UK) Limited
Phase 2/3
222
Alabama, Colorado, Florida, Georgia, Michigan, Mississippi, North Carolina, Ohio
2026-05-29
Recruiting
Pfizer
Phase 3
3,230
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-05-29
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-28
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Maryland, Michigan
2026-05-27
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
250
California, Florida, Georgia, Maryland, Michigan, New York, Ohio, Pennsylvania
2026-05-25
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Arizona, California, Colorado, Florida, Georgia, Kentucky, Louisiana, Missouri
2026-05-23
Recruiting
Regeneron Pharmaceuticals
Phase 1
160
Alabama, Arkansas, California, Florida, Georgia, South Carolina, Texas
2026-05-22
Active, closed
Kite, A Gilead Company
Phase 3
550
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2026-05-22
Recruiting
Eli Lilly and Company
Phase 3
550
Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa
2026-05-22
Recruiting
Revolution Medicines, Inc.
Phase 3
670
Arizona, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota
2026-05-22
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Arizona, California, Colorado, Florida, Georgia, Kentucky, Louisiana, Missouri
2026-05-22
Recruiting
Regeneron Pharmaceuticals
Phase 3
270
Arizona, Georgia, Massachusetts, Michigan, Minnesota, Missouri, New York, Ohio
2026-05-21
Recruiting
Takeda
Phase 3
300
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Kentucky
2026-05-21
Recruiting
Novo Nordisk A/S
Phase 3
2,500
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-21
Recruiting
Alpha Cognition, Inc
Phase 4
150
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2026-05-20
Recruiting
Lumos Pharma
Phase 3
150
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Indiana, Iowa
2026-05-20
Active, closed
Novo Nordisk A/S
Phase 3
985
Florida, Georgia, Idaho, Maryland, Michigan, Texas, Virginia
2026-05-20
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2026-05-20
Recruiting
Incyte Corporation
Phase 2
60
California, District of Columbia, Florida, Georgia, New York, North Carolina, Pennsylvania, Washington
2026-05-20
Recruiting
Aspeya, Inc.
Phase 2
108
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Missouri, Nevada
2026-05-19
Recruiting
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
NCT07278479Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC)
Molecular Partners AG
Phase 1/2
138
Florida, Georgia, Illinois, Maryland, Nebraska, New Jersey, Ohio, Texas
2026-05-18
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 2
180
Arizona, California, Florida, Georgia, Illinois, Indiana, Missouri, Nebraska
2026-05-18
Recruiting
Ipsen
Phase 3
350
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-05-14
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
Dyne Therapeutics
Phase 3
150
California, Florida, Georgia, Indiana, Maryland, Missouri, New York, North Carolina
2026-05-14
Recruiting
RAI Services Company
Not applicable
1,280
Florida, Georgia, Missouri, North Carolina, Pennsylvania, Texas
2026-05-14
Recruiting
Draig Therapeutics Ltd
Phase 2
118
Arizona, Arkansas, California, Florida, Georgia, Illinois, Massachusetts, New York
2026-05-14
Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
NCT07579702Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Insulet Corporation
Not applicable
200
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Massachusetts, Michigan
2026-05-13
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 2
34
California, Florida, Georgia, Hawaii, Illinois, Nevada, North Carolina, South Carolina
2026-05-13
Recruiting
Eli Lilly and Company
Phase 2
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-05-13
Recruiting
Sanofi
Phase 3
300
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota
2026-05-12
Recruiting
A Study to Assess the Safety, Tolerability and Efficacy of ION775
NCT07604974Hypertriglyceridemia, Severe Hypertriglyceridemia
Ionis Pharmaceuticals, Inc.
Phase 2
72
California, Colorado, Florida, Georgia, Indiana, Kentucky, Michigan, Ohio
2026-05-12
Recruiting
Dompé Farmaceutici S.p.A
Phase 2
417
Arizona, California, Florida, Georgia, Indiana, Minnesota, Missouri, North Carolina
2026-05-12
Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
NCT07296744Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Supira Medical
Not applicable
358
California, Florida, Georgia, Illinois, Michigan, Minnesota, Missouri, New Jersey
2026-05-11
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2026-05-11
Recruiting
GlaxoSmithKline
Phase 3
1,209
Alabama, California, Florida, Georgia, Illinois, Michigan, Ohio, South Carolina
2026-05-11
Recruiting
Amgen
Phase 3
300
Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois
2026-05-11
Recruiting
Incyte Corporation
Phase 1
218
Alabama, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Missouri
2026-05-11
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-11
Active, closed
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity
Pfizer
Phase 2
940
Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-11
Recruiting
Definium Therapeutics US, Inc.
Phase 3
165
Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri
2026-05-10
Recruiting
Crystalys Therapeutics
Phase 2
90
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2026-05-08
Recruiting
Novartis Pharmaceuticals
Phase 2
323
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas
2026-05-07
Recruiting
AstraZeneca
Observational
2,150
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Maryland
2026-05-06
Recruiting
Novo Nordisk A/S
Phase 3
300
Arizona, Florida, Georgia, Illinois, New York, North Dakota, Ohio, Pennsylvania
2026-05-05
Recruiting
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT07326566Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)
Black Diamond Therapeutics, Inc.
Phase 2
162
Alabama, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Maine
2026-05-05
Recruiting
Novo Nordisk A/S
Phase 3
300
California, Florida, Georgia, Illinois, New York, Ohio, Pennsylvania, Texas
2026-05-05
Recruiting
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
Pfizer
Phase 3
2,400
Florida, Georgia, Idaho, Illinois, Kentucky, Louisiana, Massachusetts, Nebraska
2026-05-04
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 1/2
150
Alabama, California, Florida, Georgia, Indiana, Michigan, Minnesota, New Hampshire
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
Altesa Biosciences, Inc.
Phase 2
180
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-05-01
Recruiting
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
NCT06438471Spinal Cord Injuries, Neuropathic Pain, Degenerative Disc Disease, Spinal Stenosis
DrugEC5026
EicOsis Human Health Inc.
Phase 1
36
Georgia
2026-05-01
Active, closed
Bristol-Myers Squibb
Observational
3,000
Georgia
2026-05-01
Recruiting
Delve Bio, Inc.
Not applicable
400
California, Georgia, Maryland, Massachusetts, Tennessee
2026-05-01
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Mississippi
2026-04-30
Recruiting
Aquarius Pilot Study to Evaluate the New Axonics Trial System
NCT07335484Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI), Overactive Bladder (OAB)
Axonics, Inc.
Not applicable
75
Alabama, Georgia, Illinois, South Carolina
2026-04-30
Recruiting
Athos Therapeutics Inc
Phase 2
120
Florida, Georgia, Ohio
2026-04-30
Recruiting
Biomea Fusion Inc.
Phase 2
60
Alabama, California, Florida, Georgia, Nevada, North Carolina, Ohio, Texas
2026-04-30
Recruiting
Oncolytics Biotech
Phase 2
60
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Michigan
2026-04-30
Recruiting
Insulet Corporation
Not applicable
350
California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana, Massachusetts
2026-04-30
By invitation
Axsome Therapeutics, Inc.
Phase 3
300
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2026-04-29
Recruiting
Alnylam Pharmaceuticals
Phase 2
93
California, Florida, Georgia
2026-04-27
Recruiting
Bristol-Myers Squibb
Phase 1
64
Georgia, Texas
2026-04-27
Recruiting
Phase 2 Study to Assess the Safety and Efficacy of ANG003
NCT07450547Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Anagram Therapeutics, Inc.
Phase 2
113
California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky
2026-04-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
California, Colorado, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Michigan
2026-04-23
Recruiting
Minerva Neurosciences
Phase 3
380
California, Florida, Georgia, Maryland, New Jersey, New York, Texas
2026-04-23
Recruiting
LB Pharmaceuticals Inc.
Phase 3
900
Arizona, Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri
2026-04-23
Recruiting
Aurinia Pharmaceuticals Inc.
Phase 4
150
California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri, Nevada
2026-04-22
Recruiting
Alkermes, Inc.
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-22
Recruiting
BioNTech SE
Phase 3
736
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, New York
2026-04-22
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2026-04-21
Recruiting
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
NCT07489651Generalized Anxiety Disorder
DrugRE104
Reunion Neuroscience Inc
Phase 2
160
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Michigan
2026-04-20
Recruiting
A Study to Evaluate the Efficacy and Safety of TP-06 for PCED
NCT07886268Persistent Corneal Epithelial Defect
Tarsus Pharmaceuticals, Inc.
Phase 2
32
Arizona, Florida, Georgia, Minnesota, New Jersey, New York, South Carolina, Texas
2026-04-20
Recruiting
EVERO Drug-coated Balloon (DCB) Randomized Trial
NCT07144150Peripheral Vascular Disease, Peripheral Arterial Disease
Cook Research Incorporated
Not applicable
410
California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Iowa, Michigan
2026-04-17
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Eli Lilly and Company
Phase 1
460
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Minnesota, New York
2026-04-17
Recruiting
SetPoint Medical Corporation
Not applicable
60
California, Georgia, Maryland, Minnesota, Texas, Washington, West Virginia, Wisconsin
2026-04-17
Recruiting
Immedica Pharma US Inc
Not applicable
100
Georgia
2026-04-17
Recruiting
Visugromab in Cachexia International Trial
NCT07112196Cancer-associated Cachexia
CatalYm GmbH
Phase 2/3
518
Connecticut, Florida, Georgia, New Jersey, Ohio
2026-04-16
Recruiting
Hoffmann-La Roche
Phase 3
100
Colorado, Connecticut, Florida, Georgia, Missouri, New York, Ohio, Pennsylvania
2026-04-15
Recruiting
GlaxoSmithKline
Phase 2
200
California, Connecticut, Florida, Georgia, Louisiana, Maryland, Missouri, New Mexico
2026-04-15
Recruiting
Regeneron Pharmaceuticals
Phase 2
120
California, Florida, Georgia, Illinois, Kentucky, Michigan, Nebraska, New York
2026-04-14
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
Eli Lilly and Company
Phase 2
66
Arizona, California, Florida, Georgia, Indiana, Massachusetts, Michigan, New Hampshire
2026-04-14
Recruiting
Ambros Therapeutics, Inc.
Phase 3
270
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2026-04-14
Recruiting
Boehringer Ingelheim
Phase 3
670
Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Maryland, Michigan
2026-04-13
Recruiting
Novo Nordisk A/S
Phase 3
400
Arizona, California, Connecticut, Florida, Georgia, Idaho, Massachusetts, Nevada
2026-04-13
Recruiting
Incyte Corporation
Phase 3
588
Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia
2026-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
California, Georgia, Kentucky, Massachusetts, Michigan, Missouri, New Jersey, New York
2026-04-09
Recruiting
GlaxoSmithKline
Phase 2
420
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-04-08
Recruiting
Medtronic Cardiac Ablation Solutions
Not applicable
400
Alabama, California, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2026-04-08
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
400
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky
2026-04-07
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
California, Colorado, Georgia, Iowa, Minnesota, New Jersey, New York, North Carolina
2026-04-07
Active, closed
Kailera
Phase 2
306
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana
2026-04-06
Recruiting
Alkermes, Inc.
Phase 3
150
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-06
Recruiting
Regeneron Pharmaceuticals
Phase 3
2,628
Alabama, Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana
2026-04-03
Recruiting
Biosense Webster, Inc.
Not applicable
566
Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Michigan, New Jersey
2026-04-02
Recruiting
Transcend Therapeutics
Phase 3
300
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Louisiana
2026-04-02
Recruiting
Sanofi
Observational
2,500
Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland
2026-04-01
Recruiting
MiRus
Not applicable
1,025
Georgia
2026-04
Recruiting
Palvella Therapeutics, Inc.
Phase 2
15
California, Georgia, Nevada, Texas
2026-04
Recruiting
MapLight Therapeutics
Phase 2
500
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2026-03-31
Recruiting
Merck Sharp & Dohme LLC
Phase 1
40
Alabama, California, Colorado, Florida, Georgia, Illinois, Michigan, Minnesota
2026-03-30
Active, closed
Biomea Fusion Inc.
Phase 2
64
Alabama, California, Florida, Georgia, Nevada, Ohio, Texas, Virginia
2026-03-27
Recruiting
Eisai Inc.
Phase 2
64
California, Florida, Georgia, Maryland, Michigan, North Carolina, South Carolina, Texas
2026-03-26
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals
Phase 2
32
California, Colorado, Georgia, Iowa, Minnesota
2026-03-26
By invitation
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
NCT07459660Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics
Phase 2
210
California, Colorado, Florida, Georgia, Ohio
2026-03-25
Recruiting
LB Pharmaceuticals Inc.
Phase 3
456
Arkansas, California, Florida, Georgia, Illinois, Missouri, Ohio
2026-03-25
Recruiting
Zydus Therapeutics Inc.
Phase 3
386
Georgia, Indiana, Texas
2026-03-24
Recruiting
Continuous Dual Aspiration Technique With Zoom System for Stroke
NCT07491952Ischemic Stroke, Acute Stroke
Imperative Care, Inc.
Observational
750
Alabama, California, Florida, Georgia, Louisiana, Maryland, Minnesota, New York
2026-03-24
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-03-24
Recruiting
Merck Sharp & Dohme LLC
Phase 2
100
California, Colorado, Florida, Georgia, Kansas, Louisiana, Missouri
2026-03-24
Active, closed
ModernaTX, Inc.
Phase 3
4,050
California, Georgia, Idaho, Maryland, Nebraska, Ohio, Rhode Island, South Carolina
2026-03-23
Active, closed
Eccogene
Phase 2
151
Alabama, California, Florida, Georgia, Minnesota, Nebraska, North Carolina, Ohio
2026-03-23
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Illinois
2026-03-23
Recruiting
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
NCT07219459Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
CatalYm GmbH
Phase 2
104
California, Georgia, Illinois, Massachusetts
2026-03-19
Recruiting
Sanofi
Observational
1,000
District of Columbia, Georgia, New York, Utah
2026-03-19
By invitation
Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF)
NCT07286201Chronic Rhinosinusitis (CRS), Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Polyganics BV
Not applicable
110
Colorado, Georgia, Illinois, Louisiana, Maryland, South Carolina, Texas, Utah
2026-03-19
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2026-03-17
Recruiting
Gilead Sciences
Observational
3,000
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2026-03-17
Recruiting
IDEAYA Biosciences
Phase 1
155
California, Connecticut, Florida, Georgia, Missouri, New Jersey, New York, Tennessee
2026-03-17
Recruiting
Bristol-Myers Squibb
Phase 3
850
Alabama, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky
2026-03-16
Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
NCT07143019Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm
phenox Inc.
Not applicable
214
Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Massachusetts
2026-03-16
Recruiting
Adverum Biotechnologies, Inc.
Phase 3
534
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-03-16
Recruiting
Harmony Biosciences Management, Inc.
Phase 3
248
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-03-16
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Alabama, Arizona, California, Connecticut, Georgia, Hawaii, Illinois, Kentucky
2026-03-16
Recruiting
Novartis Pharmaceuticals
Phase 2
142
Arkansas, California, Florida, Georgia, Illinois, Missouri
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Arizona, California, Florida, Georgia, Illinois, Iowa, Minnesota, Missouri
2026-03-13
Recruiting
Sanofi
Phase 2/3
526
California, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan, New York
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
750
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-03-12
Recruiting
HeartFlow, Inc.
Observational
5,000
California, Florida, Georgia, Illinois, Kentucky, Michigan, Minnesota, New Jersey
2026-03-11
Recruiting
Pfizer
Phase 1/2
132
Arkansas, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2026-03-11
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
EMD Serono Research & Development Institute, Inc.
Phase 3
202
California, Florida, Georgia, Michigan, Texas
2026-03-10
Recruiting
GlaxoSmithKline
Phase 1
225
Alabama, Arkansas, California, Florida, Georgia, Texas, Virginia, Washington
2026-03-09
Recruiting
Incyte Corporation
Phase 3
700
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-03-05
Recruiting
Janssen Research & Development, LLC
Phase 3
600
California, Colorado, Florida, Georgia, Illinois, Louisiana, Michigan, New Jersey
2026-03-05
Recruiting
Hutchmed
Phase 1/2
186
California, Florida, Georgia, Washington
2026-03-04
Active, closed
Kailera
Phase 2
264
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-03-04
Active, closed
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
Tenax Therapeutics, Inc.
Phase 3
540
Alabama, Arizona, California, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2026-03-03
Recruiting
Janssen Research & Development, LLC
Phase 1
64
California, Georgia, Illinois, Michigan, New York, Texas
2026-03-02
Active, closed
Bactolife A/S
Observational
60
Georgia, Michigan, Minnesota, Wisconsin
2026-03-01
Not yet open
BetterMe Limited
Not applicable
300
Georgia
2026-03
Recruiting
AbbVie
Phase 1
127
California, Colorado, Florida, Georgia, Illinois, Michigan
2026-02-27
Recruiting
Boehringer Ingelheim
Phase 2
30
Arizona, California, Colorado, Florida, Georgia, Iowa, Kansas, Maryland
2026-02-27
Recruiting
Bristol-Myers Squibb
Observational
1,500
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-02-26
Recruiting
Appello Pharmaceuticals, Inc.
Phase 2
150
Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky
2026-02-25
Recruiting
Novo Nordisk A/S
Phase 3
1,150
Florida, Georgia, Illinois, Indiana, Missouri, New York, North Carolina, Pennsylvania
2026-02-24
Active, closed
Pfizer
Phase 3
1,078
California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska, New Jersey
2026-02-24
Recruiting
REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
NCT07280065PTSD - Post Traumatic Stress Disorder
Senseye, Inc.
Phase 3
1,900
Colorado, Georgia, Idaho, Massachusetts, South Carolina
2026-02-23
Recruiting
Pfizer
Phase 2
770
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Missouri
2026-02-23
Recruiting
AstraZeneca
Phase 3
508
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-02-23
Recruiting
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
NCT07484217Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Axsome Therapeutics, Inc.
Phase 3
508
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada
2026-02-23
Recruiting
Kyntra Bio
Phase 2
75
Arizona, California, Connecticut, Florida, Georgia, Louisiana, New Mexico, North Carolina
2026-02-22
Active, closed
AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
NCT07368959Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Aurion Biotech
Phase 3
130
Arizona, Arkansas, Colorado, Georgia, Missouri, North Carolina, Pennsylvania, South Carolina
2026-02-19
Recruiting
C4 Therapeutics, Inc.
Phase 2
100
Alabama, Arizona, California, Florida, Georgia, Indiana, Iowa, Massachusetts
2026-02-18
Active, closed
Ipsen
Phase 3
1,305
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana
2026-02-18
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Indiana, Kentucky
2026-02-17
Recruiting
Electra Therapeutics Inc.
Phase 1
84
Connecticut, Georgia, Michigan, New York, Ohio, Texas
2026-02-17
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
240
California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Louisiana
2026-02-16
Recruiting
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-02-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Alabama, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2026-02-16
Recruiting
Boehringer Ingelheim
Phase 3
286
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-02-16
Recruiting
Amicus Therapeutics
Observational
450
Alabama, Arkansas, Georgia, Missouri, New York, Pennsylvania, Texas, Virginia
2026-02-13
Recruiting
Elion Therapeutics, Inc.
Phase 2
60
Alabama, California, Georgia, Maryland, Massachusetts, Michigan, Missouri, Texas
2026-02-13
Recruiting
Eli Lilly and Company
Phase 2
465
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-02-13
Recruiting
ViiV Healthcare
Phase 2
186
California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky, Missouri
2026-02-11
Recruiting
Pfizer
Phase 2/3
1,156
Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana
2026-02-11
Recruiting
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
NCT07285785Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea
Bausch Health Americas, Inc.
Phase 4
54
California, Florida, Georgia, Illinois, Oregon, Texas, Virginia
2026-02-11
Recruiting
Eli Lilly and Company
Phase 3
900
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-02-10
Active, closed
Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.
Phase 2
8
Arizona, California, Colorado, Florida, Georgia, Illinois, North Carolina, North Dakota
2026-02-10
Recruiting
Pfizer
Phase 1/2
224
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
800
Alabama, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2026-02-10
Recruiting
Eli Lilly and Company
Phase 2
450
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
California, Connecticut, Florida, Georgia, Indiana, Iowa, Maryland, Massachusetts
2026-02-09
Recruiting
i-SENS, Inc.
Not applicable
32
California, Georgia, Washington
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
900
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-02-09
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2026-02-08
Recruiting
Neurocrine Biosciences
Phase 2
100
Arkansas, California, Florida, Georgia, Illinois, Michigan, Missouri, Nebraska
2026-02-06
Active, closed
Corxel Pharmaceuticals
Phase 2
251
Alabama, California, Florida, Georgia, Illinois, Indiana, Maryland, Michigan
2026-02-06
Recruiting
Eli Lilly and Company
Phase 3
1,980
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Iowa
2026-02-06
Recruiting
C4 Therapeutics, Inc.
Phase 1
60
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-02-06
Recruiting
Vima Therapeutics
Phase 2
100
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-02-05
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-02-04
Recruiting
AbbVie
Phase 2
195
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Missouri
2026-02-03
Active, closed
Medtronic MiniMed, Inc.
Not applicable
389
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2026-02-02
Recruiting
Incyte Corporation
Phase 2
40
Alabama, Arizona, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2026-02-02
Recruiting
CSL Behring
Phase 2
63
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, Minnesota, Mississippi
2026-02-02
Recruiting
Prilenia
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland
2026-02-01
Recruiting
Genmab
Phase 2
240
California, District of Columbia, Florida, Georgia, Montana, Nebraska, New Jersey, New York
2026-01-30
Recruiting
Bausch Health Americas, Inc.
Phase 3
350
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-01-29
Recruiting
Bristol-Myers Squibb
Phase 3
166
California, Florida, Georgia, Illinois, Massachusetts, New Jersey, New York, Ohio
2026-01-29
Recruiting
Kymera Therapeutics, Inc.
Phase 2
264
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kansas, Kentucky
2026-01-28
Recruiting
Corcept Therapeutics
Phase 2
80
Arizona, California, Florida, Georgia, Indiana, Kansas, Michigan, Minnesota
2026-01-27
By invitation
Immunovant Sciences GmbH
Phase 2
372
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2026-01-26
Recruiting
Rigicon, Inc.
Not applicable
182
Florida, Georgia, Texas
2026-01-26
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
45
Alabama, California, Florida, Georgia, Massachusetts, New York, North Carolina, Pennsylvania
2026-01-26
Recruiting
Newron Pharmaceuticals SPA
Phase 3
400
California, Florida, Georgia, Maryland, New York
2026-01-23
Recruiting
LB Pharmaceuticals Inc.
Phase 2
320
Arkansas, California, Florida, Georgia, Illinois, Michigan, Missouri, Nevada
2026-01-23
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
CellCentric Ltd.
Phase 2
100
Arizona, California, Florida, Georgia, Illinois, Iowa, Maryland, Massachusetts
2026-01-22
Recruiting
Sanofi
Phase 3
100
Georgia, Nebraska, New Jersey, Texas
2026-01-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Alabama, Alaska, California, Florida, Georgia, Louisiana, Maryland, Minnesota
2026-01-19
Recruiting
Supernus Pharmaceuticals, Inc.
Phase 2
230
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-01-19
Recruiting
Boehringer Ingelheim
Phase 3
400
California, District of Columbia, Florida, Georgia, Idaho, Illinois, Massachusetts, Nevada
2026-01-16
Recruiting
Sanofi
Phase 3
751
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2026-01-16
Recruiting
Cartography Biosciences
Phase 1
80
Arizona, California, Florida, Georgia, Michigan, Texas, Virginia
2026-01-15
Recruiting
Celldex Therapeutics
Phase 3
240
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Kentucky
2026-01-15
Active, closed
Janssen Research & Development, LLC
Phase 2
157
Arkansas, California, Florida, Georgia, Illinois, Indiana, New Mexico, North Carolina
2026-01-15
Active, closed
Medtronic Cardiac Ablation Solutions
Not applicable
300
Arkansas, California, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota
2026-01-15
Recruiting
Servier Bio-Innovation LLC
Phase 1
30
Georgia, Ohio, Texas
2026-01-14
Recruiting
Sanofi
Phase 3
160
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland
2026-01-14
Recruiting
Axsome Therapeutics, Inc.
Phase 3
620
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas
2026-01-14
Recruiting
Renibus Therapeutics, Inc.
Phase 3
150
California, Colorado, Delaware, Florida, Georgia, Idaho, Illinois, Indiana
2026-01-13
Recruiting
Ardelyx
Phase 3
692
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-01-13
Active, closed
Kailera
Phase 3
1,270
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2026-01-12
Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07188558Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Lyell Immunopharma, Inc.
Phase 3
400
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2026-01-12
Recruiting
BillionToOne Inc.
Observational
1,000
Arizona, California, Florida, Georgia, Louisiana, New York, Texas
2026-01-10
Recruiting
Enveda Therapeutics
Phase 2
50
Alabama, California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky
2026-01-09
Recruiting
A Study of Buntanetap in Participants With PD
NCT07284784Parkinson's Disease (PD), Deep Brain Stimulation
Annovis Bio Inc.
Phase 2/3
500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2026-01-09
Recruiting
Regeneron Pharmaceuticals
Phase 2
195
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-01-09
Active, closed
Hoffmann-La Roche
Phase 2
120
California, Florida, Georgia, Michigan, Minnesota, Pennsylvania
2026-01-08
Recruiting
Janssen Research & Development, LLC
Phase 3
258
Alabama, Connecticut, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Minnesota
2026-01-08
Active, closed
Invivyd, Inc.
Phase 3
1,770
California, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2026-01-08
Recruiting
Amicus Therapeutics
Phase 3
8
Georgia, Minnesota, North Carolina, Ohio, Pennsylvania, Virginia
2026-01-08
Recruiting
Novo Nordisk A/S
Phase 3
460
California, Florida, Georgia, Idaho, Indiana, Kansas, Louisiana, Maryland
2026-01-08
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer
Phase 3
1,410
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas
2026-01-06
Recruiting
Disc Medicine, Inc
Phase 1
24
Alabama, California, Georgia, Illinois, Indiana, New York, North Carolina, Ohio
2026-01-06
Recruiting
Syndeio Biosciences, Inc
Phase 2
164
Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts
2026-01-05
Recruiting
Regeneron Pharmaceuticals
Phase 3
915
Georgia, Michigan, New York, Ohio, Texas
2026-01-02
Recruiting
Theradex
Phase 2
66
Florida, Georgia, Minnesota, Texas
2026-01-01
Not yet open
Greg Bew
Phase 2
100
Georgia
2026-01-01
Recruiting
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients
NCT06615635Squamous Cell Carcinoma, Alpha Radiation, Immunocompromised, Carcinoma, Squamous
Alpha Tau Medical LTD.
Not applicable
28
Arizona, Florida, Georgia, Minnesota, New York
2026-01-01
Active, closed
Acepodia Biotech, Inc.
Phase 1/2
34
Georgia, Massachusetts
2026-01-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa
2025-12-31
Active, closed
Kailera
Phase 3
1,270
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas
2025-12-30
Recruiting
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
NCT07351071Colorectal Anastomosis, Left-sided Colon Resection, Anastomotic Leak, Anastomotic Complication
Medtronic - MITG
Not applicable
137
Connecticut, Florida, Georgia, Massachusetts, Minnesota, North Carolina, Ohio, Pennsylvania
2025-12-30
Active, closed
UCB Biopharma SRL
Phase 2
165
California, Florida, Georgia, Illinois, Indiana, Kentucky, Michigan, Nebraska
2025-12-29
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals
Phase 1/2
205
Georgia, Tennessee, Texas
2025-12-29
Active, closed
Organon and Co
Phase 3
187
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-12-29
Recruiting
Sanofi
Phase 2
144
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts
2025-12-29
Recruiting
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
Phase 1/2
164
California, Georgia, Minnesota, Missouri, Texas
2025-12-29
Recruiting
Neurocrine Biosciences
Phase 2
150
Arkansas, California, Florida, Georgia, Maryland, New Jersey, New York, Texas
2025-12-24
Recruiting
Protalix
Phase 2
150
Arizona, Arkansas, California, Florida, Georgia, Michigan, Pennsylvania, Texas
2025-12-22
Recruiting
Tyra Biosciences, Inc
Phase 2
285
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2025-12-22
Recruiting
Taiho Oncology, Inc.
Phase 3
360
Alaska, California, District of Columbia, Florida, Georgia, Illinois, Michigan, New Jersey
2025-12-22
Recruiting
Enveda Therapeutics
Phase 2
105
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-12-22
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-12-19
Rows per page Showing 1–500 of 2364
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 November 2026. https://priyalifescience.com/clinical-trials-usa/state/georgia

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 22 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,364 of those studies with a site in Georgia.

How many clinical trials are recruiting in Georgia?

1,225 of the 2,364 studies on this page are recruiting new participants as of the 22 Nov 2026, 03:16 UTC sync. A further 32 have not yet opened recruitment, 1,047 are active but closed to new participants, and 60 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Georgia), 2,364 studies
PhaseStudiesRecruitingShare
Phase 397347641.2%
Phase 244724718.9%
Not applicable28712712.1%
Observational186927.9%
Phase 11721077.3%
Phase 1/2155926.6%
Phase 2/385503.6%
Phase 459342.5%

Most active sponsors

Lead sponsors with the most studies (Georgia)
Lead sponsorStudiesRecruiting
AstraZeneca10458
Eli Lilly and Company9255
Merck Sharp & Dohme LLC7231
AbbVie6928
Janssen Research & Development, LLC6628
Novartis Pharmaceuticals6532
Pfizer5133
Sanofi5027
Bristol-Myers Squibb4830
Hoffmann-La Roche4720
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.